CN103169778A - Medicament for treating lung cancer and preparation method thereof - Google Patents
Medicament for treating lung cancer and preparation method thereof Download PDFInfo
- Publication number
- CN103169778A CN103169778A CN201310090919XA CN201310090919A CN103169778A CN 103169778 A CN103169778 A CN 103169778A CN 201310090919X A CN201310090919X A CN 201310090919XA CN 201310090919 A CN201310090919 A CN 201310090919A CN 103169778 A CN103169778 A CN 103169778A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- radix
- following weight
- weight proportioning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal preparation for treating and preventing lung cancer. The medicinal composition comprises adder-wort, trichosanthes peel, astragalus and other traditional Chinese medicines, and various oral preparations can be prepared from the medicinal preparation according to clinical requirements. The medicinal composition has an excellent effect for treating and preventing lung cancer.
Description
Technical field
The invention discloses the pharmaceutical preparation of a kind for the treatment of and prevention pulmonary carcinoma, formed by Chinese medicines such as Rhizoma Bistortae, Pericarpium Trichosanthis, Radix Panacis Quinquefolii and the Radixs Astragali, can be prepared into various dosage forms according to clinical needs.This pharmaceutical composition has very excellent treatment and preventive effect for pulmonary carcinoma.
Background technology
Pulmonary carcinoma is a kind of common pulmonary malignant tumour, and most pulmonary carcinoma originate from the bronchial mucosa epithelium.In recent years, along with the impact of smoking and various environmental factorss, countries in the world are industrially developed country particularly, and the sickness rate of pulmonary carcinoma and case fatality rate all rise rapidly, dies from that in the male patient of carninomatosis, pulmonary carcinoma ranks first.According to latest data, malignant tumor has become the first place of China urbanite cause of death, account for 25% of whole dead sums, and lung cancer morbidity rate ascensional range is maximum, risen 465% in 30 years in the past, and replaced hepatocarcinoma to become the first Death Cause for Malignant Tumors of China.Especially big and medium-sized cities such as Beijing, Shanghai, Guangzhou, Nanjing, the morbidity of pulmonary carcinoma and mortality rate have occupied the first place of various oncosises.
Shanghai City statistics of male lung cancer morbidity rate in 1996 is that its sickness rate in 74.76/10 ten thousand, 2000 has risen to 83.43/10 ten thousand; Jiangsu is tumor province occurred frequently, and the M ﹠ M of malignant tumor is all far away higher than average national level.In the tumor invasion situation of this area, pulmonary carcinoma is only second to hepatocarcinoma and human primary gastrointestinal cancers, and the sickness rate of pulmonary carcinoma constantly rises.ASSOCIATE STATISTICS is found, the Jiangsu lung cancer mortality has accounted for the first place that in the city, cancer is died, the Xuzhou Urban District ' that the lung cancer death level is the highest, pulmonary carcinoma accounts for 24.57% of malignant tumor cause of the death formation, in every 4 cancer persons of dying, just have 1 people to die from pulmonary carcinoma, the proportion of pulmonary carcinoma in various fatal diseases is also startling, in every dead 17 people of local resident, just there is 1 people to die from pulmonary carcinoma.
According to the data prediction that health ministry whole nation treatment and prevention of tumour research office provides, between 2000 to 2005, the number of the infected of lung cancer in China increases by 120,000, the male from 2000 260,000 increase to 2005 330,000, increase by 26.9%; The women increases to 170,000 from 120,000.According to epidemiological specialist prediction, if do not control smoking and air pollution, by 2025, the annual patients with lung cancer of China will be over 1,000,000, became the first in the world pulmonary carcinoma big country.
For the treatment of pulmonary carcinoma, mostly advocate at present operative treatment as early as possible, excise to greatest extent pulmonary carcinoma and keep to greatest extent pulmonary function, postoperative carries out radiotherapy or chemotherapy to the patient simultaneously.But from above-mentioned mortality rate, therapeutic effect is obviously very undesirable.In addition, local advanced non small cell lung cancer that can not excision accounts for 1/3 of pulmonary carcinoma sum.Both having made and having adopted above-mentioned treatment means, the life cycle of most of patients is 9-10 month, and 5 years survival rates are only 3-10%; Patient over half dies from metastasis.And radiation and chemotherapy all brings the health of human normal tissue and seriously influences.Treatment of Lung Cancer with Chinese Medicine be also generally toxic and side effects and the relief of symptoms of alleviating chemicotherapy be main.
Therefore, seeking a kind of effective medicine for pulmonary carcinoma is the research direction that the world of medicine pays close attention to.
Summary of the invention
The invention provides a kind of pharmaceutical composition, have the effect of supplementing QI and nourishing YIN, heat-clearing and toxic substances removing, dissipating phlegm and removing blood stasis, can effectively treat and prevent pulmonary carcinoma, suitable especially treatment pulmonary carcinoma deficiency of both QI and YIN, pyretic toxicity pent up, the stagnant card of expectorant stasis blocking.This medicine is not only evident in efficacy, and there is no obvious side effect fully.
This pharmaceutical composition is made by the component of following weight proportioning: Rhizoma Bistortae 50-150 part, Pericarpium Trichosanthis 50-150 part, Radix Astragali 150-350 part, Radix Panacis Quinquefolii 25-70 part, Fructus Forsythiae 80-180 part, Herba Taraxaci 80-180 part, Radix Trichosanthis 25-80 part.
Preferred pharmaceutical composition is made by the component of following weight proportioning: Rhizoma Bistortae 60-110 part, Pericarpium Trichosanthis 60-110 part, Radix Astragali 180-250 part, Radix Panacis Quinquefolii 30-55 part, Fructus Forsythiae 90-120 part, Herba Taraxaci 90-120 part, Radix Trichosanthis 30-55 part.
Most preferred pharmaceutical composition is made by the component of following weight proportioning: 65 parts of Rhizoma Bistortaes, 65 parts of Pericarpium Trichosanthiss, 200 parts of the Radixs Astragali, 40 parts of Radix Panacis Quinquefoliis, 100 parts of Fructus Forsythiaes, 100 parts of Herba Taraxacis, 40 parts of Radix Trichosanthis.
In addition, on the basis of aforementioned pharmaceutical compositions, also can increase any one or more components of following weight proportioning: Rhizoma Curcumae 45-150 part, Bulbus Fritillariae Thunbergii 45-150 part; The preferred weight proportioning of described increase component is: Rhizoma Curcumae 55-100 part, Bulbus Fritillariae Thunbergii 55-100 part; The most preferably weight proportion of described increase component is: 65 parts of Rhizoma Curcumae, 65 parts of Bulbus Fritillariae Thunbergiis.
In addition, according to the dialectical difference of individual patients, can also carry out some flexible adjustment to above-mentioned prescription, include but not limited to: increase or alleviate part or all of prescription consumption; Delete the part component; Increase or replace some supplementing QI and nourishing YIN, heat-clearing and toxic substances removing, dissipating phlegm and removing blood stasis Chinese medicine.Undoubtedly, within these adjustment all should be included in the present invention.
Pharmaceutical composition of the present invention can be prepared as various dosage forms, includes but not limited to: decoction, tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, sublimed preparation, suspensoid, powder, solution, injection and drop etc.
Wherein, the preferred dosage form of pharmaceutical composition of the present invention is pill, capsule, granule, tablet or decoction, described flavour of a drug is boiled or pulverizes rear preparation with decocting and get final product.Preparation method is comparatively simple, taking convenience, and utilization ratio of drug is higher.
Content of the present invention also comprises the application of this pharmaceutical composition in the medicine of preparation treatment and prevention pulmonary carcinoma.
The present invention is described further by the following examples.
The specific embodiment
Embodiment 1
Prescription: 50 parts of Rhizoma Bistortaes, 150 parts of Pericarpium Trichosanthiss, 150 parts of the Radixs Astragali, 70 parts of Radix Panacis Quinquefoliis, 80 parts of Fructus Forsythiaes, 180 parts of Herba Taraxacis, 80 parts of Radix Trichosanthis.
Method for making: above-mentioned flavour of a drug are ground into fine powder, sieve, and mixing is used water pill, and drying namely gets pill.
Embodiment 2
Prescription: 150 parts of Rhizoma Bistortaes, 50 parts of Pericarpium Trichosanthiss, 350 parts of the Radixs Astragali, 25 parts of Radix Panacis Quinquefoliis, 180 parts of Fructus Forsythiaes, 80 parts of Herba Taraxacis, 25 parts of Radix Trichosanthis.
Method for making: above-mentioned flavour of a drug, boil twice with decocting, each 1-2 hour, collecting decoction filtered, and namely gets decoction.
Embodiment 3
Prescription: 60 parts of Rhizoma Bistortaes, 110 parts of Pericarpium Trichosanthiss, 180 parts of the Radixs Astragali, 55 parts of Radix Panacis Quinquefoliis, 120 parts of Fructus Forsythiaes, 90 parts of Herba Taraxacis, 55 parts of Radix Trichosanthis.
Method for making: above-mentioned flavour of a drug are ground into fine powder, sieve, and mixing incapsulates, and namely get capsule.
Embodiment 4
Prescription: 110 parts of Rhizoma Bistortaes, 60 parts of Pericarpium Trichosanthiss, 250 parts of the Radixs Astragali, 30 parts of Radix Panacis Quinquefoliis, 90 parts of Fructus Forsythiaes, 120 parts of Herba Taraxacis, 30 parts of Radix Trichosanthis.
Method for making: after above-mentioned flavour of a drug water decoction-alcohol sedimentation, filter, the filtrate concentrate drying adds dextrin, is made as granule, in the bag of packing into, namely gets granule.
Embodiment 5
Prescription: 65 parts of Rhizoma Bistortaes, 65 parts of Pericarpium Trichosanthiss, 200 parts of the Radixs Astragali, 40 parts of Radix Panacis Quinquefoliis, 100 parts of Fructus Forsythiaes, 100 parts of Herba Taraxacis, 30 parts of Radix Trichosanthis.
Method for making: after above-mentioned flavour of a drug water decoction-alcohol sedimentation, filter, the filtrate concentrate drying adds dextrin, is compressed to sheet, namely gets tablet.
Embodiment 6
Prescription: 50 parts of Rhizoma Bistortaes, 50 parts of Pericarpium Trichosanthiss, 350 parts of the Radixs Astragali, 70 parts of Radix Panacis Quinquefoliis, 180 parts of Fructus Forsythiaes, 80 parts of Herba Taraxacis, 25 parts of Radix Trichosanthis, 45 parts of Rhizoma Curcumae, 150 parts of Bulbus Fritillariae Thunbergiis.
Method for making: same embodiment.
Embodiment 7
Prescription: 150 parts of Rhizoma Bistortaes, 150 parts of Pericarpium Trichosanthiss, 150 parts of the Radixs Astragali, 25 parts of Radix Panacis Quinquefoliis, 80 parts of Fructus Forsythiaes, 180 parts of Herba Taraxacis, 80 parts of Radix Trichosanthis, 150 parts of Rhizoma Curcumae, 45 parts of Bulbus Fritillariae Thunbergiis.
Method for making: same embodiment.
Embodiment 8
Prescription: 60 parts of Rhizoma Bistortaes, 60 parts of Pericarpium Trichosanthiss, 250 parts of the Radixs Astragali, 30 parts of Radix Panacis Quinquefoliis, 120 parts of Fructus Forsythiaes, 120 parts of Herba Taraxacis, 30 parts of Radix Trichosanthis, 55 parts of Rhizoma Curcumae, 100 parts of Bulbus Fritillariae Thunbergiis.
Method for making: same embodiment.
Embodiment 9
Prescription: 110 parts of Rhizoma Bistortaes, 110 parts of Pericarpium Trichosanthiss, 180 parts of the Radixs Astragali, 55 parts of Radix Panacis Quinquefoliis, 90 parts of Fructus Forsythiaes, 90 parts of Herba Taraxacis, 55 parts of Radix Trichosanthis, 100 parts of Rhizoma Curcumae, 55 parts of Bulbus Fritillariae Thunbergiis.
Method for making: same embodiment.
Embodiment 10
Prescription: 65 parts of Rhizoma Bistortaes, 65 parts of Pericarpium Trichosanthiss, 200 parts of the Radixs Astragali, 40 parts of Radix Panacis Quinquefoliis, 100 parts of Fructus Forsythiaes, 100 parts of Herba Taraxacis, 40 parts of Radix Trichosanthis, 65 parts of Rhizoma Curcumae, 65 parts of Bulbus Fritillariae Thunbergiis.
Method for making: same embodiment.
Embodiment 11
The present invention has carried out clinical observation to the pharmaceutical composition for preparing in above-described embodiment 1-10, and result shows that the present invention has very excellent treatment and preventive effect to pulmonary carcinoma.
110 routine clinical patients are divided into matched group and embodiment 1-10 group at random.Matched group (chemotherapy group) adopts paclitaxel 135mg/m
2, d1 adds quiet 180min of normal saline 500ml; Cisplatin 30mg/m
2, d1～3, quiet, conventional administration Polyglucan reaction and digestive tract reaction before chemotherapy, 21d is a cycle.Embodiment 1-10 group is adopting above-mentioned therapeutic scheme (the dosage usage is the same) simultaneously, increases the pharmaceutical preparation of taking embodiment of the present invention 1-10.Every example is all completed the chemotherapy in 2 cycles.
It is difficult that short term effect is pressed WHO solid tumor curative effect mark, namely alleviates (CR), partial rcsponse (PR), stable (SD) and progress (PD) fully; Total remission rate is CR+PR.Experimental result is as follows:
Claims (9)
- One kind the treatment and the prevention pulmonary carcinoma pharmaceutical composition, made by the component of following weight proportioning:Rhizoma Bistortae 50-150 part, Pericarpium Trichosanthis 50-150 part, Radix Astragali 150-350 part, Radix Panacis Quinquefolii 25-70 part, Fructus Forsythiae 80-180 part, Herba Taraxaci 80-180 part, Radix Trichosanthis 25-80 part.
- 2. pharmaceutical composition as described in claim 1, is characterized in that, made by the component of following weight proportioning:Rhizoma Bistortae 60-110 part, Pericarpium Trichosanthis 60-110 part, Radix Astragali 180-250 part, Radix Panacis Quinquefolii 30-55 part, Fructus Forsythiae 90-120 part, Herba Taraxaci 90-120 part, Radix Trichosanthis 30-55 part.
- 3. the pharmaceutical composition described in claim 1-2, is characterized in that, made by the component of following weight proportioning:65 parts of Rhizoma Bistortaes, 65 parts of Pericarpium Trichosanthiss, 200 parts of the Radixs Astragali, 40 parts of Radix Panacis Quinquefoliis, 100 parts of Fructus Forsythiaes, 100 parts of Herba Taraxacis, 40 parts of Radix Trichosanthis.
- 4. the pharmaceutical composition described in claim 1-3, is characterized in that, also comprises any one or more components of following weight proportioning in its prescription:Rhizoma Curcumae 45-150 part, Bulbus Fritillariae Thunbergii 45-150 part.
- 5. the pharmaceutical composition described in claim 1-3, is characterized in that, also comprises any one or more components of following weight proportioning in its prescription:Rhizoma Curcumae 55-100 part, Bulbus Fritillariae Thunbergii 55-100 part.
- 6. the pharmaceutical composition described in claim 1-3, is characterized in that, also comprises any one or more components of following weight proportioning in its prescription:65 parts of Rhizoma Curcumae, 65 parts of Bulbus Fritillariae Thunbergiis.
- 7. the pharmaceutical composition described in claim 1-6, it can be prepared as various dosage forms, includes but not limited to: decoction, tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, sublimed preparation, suspensoid, powder, solution, injection and drop.
- 8. pharmaceutical composition as described in claim 7, its dosage form is pill, capsule, granule, tablet or decoction.
- 9. the application of the pharmaceutical composition described in claim 1-8 in the medicine of preparation treatment and prevention pulmonary carcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310090919.XA CN103169778B (en) | 2013-03-12 | 2013-03-12 | Medicament for treating lung cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310090919.XA CN103169778B (en) | 2013-03-12 | 2013-03-12 | Medicament for treating lung cancer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103169778A true CN103169778A (en) | 2013-06-26 |
| CN103169778B CN103169778B (en) | 2015-07-22 |
Family
ID=48630265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310090919.XA Expired - Fee Related CN103169778B (en) | 2013-03-12 | 2013-03-12 | Medicament for treating lung cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103169778B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977257A (en) * | 2014-05-23 | 2014-08-13 | 李绍益 | Medicinal composition for treating lung cancer |
| CN105770202A (en) * | 2016-04-05 | 2016-07-20 | 哈尔滨商业大学 | Pharmaceutical composition for treating lung cancer and preparation method of pharmaceutical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936619A (en) * | 1982-08-23 | 1984-02-28 | Tsumura Juntendo Inc | Carcinostatic adjuvant |
| JPS6025933A (en) * | 1983-07-22 | 1985-02-08 | Tsumura Juntendo Inc | Agent for mitigating symptoms of cancer |
| CN1557382A (en) * | 2004-02-11 | 2004-12-29 | 武汉化工学院 | Glucoside compound preparation and its preparing process |
| CN1954840A (en) * | 2005-10-26 | 2007-05-02 | 黄振华 | Medical composite prepared by Gynostemma pentaphylla, American ginseng and astragalus root |
-
2013
- 2013-03-12 CN CN201310090919.XA patent/CN103169778B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936619A (en) * | 1982-08-23 | 1984-02-28 | Tsumura Juntendo Inc | Carcinostatic adjuvant |
| JPS6025933A (en) * | 1983-07-22 | 1985-02-08 | Tsumura Juntendo Inc | Agent for mitigating symptoms of cancer |
| CN1557382A (en) * | 2004-02-11 | 2004-12-29 | 武汉化工学院 | Glucoside compound preparation and its preparing process |
| CN1954840A (en) * | 2005-10-26 | 2007-05-02 | 黄振华 | Medical composite prepared by Gynostemma pentaphylla, American ginseng and astragalus root |
Non-Patent Citations (3)
| Title |
|---|
| 侯又白: "《中医养生秘方》", 31 January 2008, 团结出版社 * |
| 张霆: "肺癌治疗中扶正与祛邪关系的思考", 《吉林中医药》 * |
| 郑红刚等，: "肺瘤平膏及其拆方对Lewis肺癌移植瘤的抑瘤作用及对S2-100蛋白和VEGF表达的影响", 《中国中医基础医学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977257A (en) * | 2014-05-23 | 2014-08-13 | 李绍益 | Medicinal composition for treating lung cancer |
| CN105770202A (en) * | 2016-04-05 | 2016-07-20 | 哈尔滨商业大学 | Pharmaceutical composition for treating lung cancer and preparation method of pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103169778B (en) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041312B (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN102988821A (en) | Chinese medicine composition for treating carcinomatosis postoperation, postchemotherapy and postradiotherapy and preparation method of Chinese medicine composition | |
| CN101352557B (en) | Chinese medicine preparation for treating gastric cancer and preparation method thereof | |
| CN104352608B (en) | A kind of benefiting QI for activating blood circulation, hard masses softening and resolving, the Chinese medicine and preparation method thereof of removing toxic substances pain relieving | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN102698227A (en) | Chinese medicine for treating constipation | |
| CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN103386078A (en) | Application of traditional Chinese medicinal composition in preparation of medicines for treating colon cancer | |
| CN102688317B (en) | Traditional Chinese medicine for treating liver cancer | |
| CN103169779B (en) | A kind of pharmaceutical composition for the treatment of pulmonary carcinoma | |
| CN103169778B (en) | Medicament for treating lung cancer and preparation method thereof | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN102028924A (en) | Medicinal composition for late gastric cancer | |
| CN104888128A (en) | Traditional Chinese medicine composition for treatment of cancers | |
| CN106138697B (en) | Chinese medicinal composition for preventing complications and relieving side effects of radiotherapy and chemotherapy of tumor patients | |
| CN101549032B (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug | |
| CN100411663C (en) | Anticancer compound Chinese medicine powder and its preparing method | |
| CN103768519B (en) | A kind of compound medicine improving cyclophosphamide antitumor curative effect and preparation method thereof | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN103202886A (en) | Traditional chinese medicine composition and preparation method thereof | |
| CN102526630B (en) | Chinese medicine for treating esophagus cancer and preparation method and administration way thereof | |
| CN101524436A (en) | Chinese medicinal composition for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150722 |